YOUR SEARCH FOR Text 29 RESULTS
1 of Total
Privacy Policy | Incyte.com
… website, website traffic patterns, and website usage 4 If, in the future, we sell or transfer … features and apps to post or upload messages, comments, screen names, files and other …
2 of Total
Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… perceptions of Opzelura to drive increased usage in mild to moderate AD patients. Opzelura … INCYTE CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited, in thousands) …
3 of Total
Contact Us | Incyte.com.com
… Events - Outside of the U.S. Required field. Message 200 character(s) left Required field. … information you provide to respond to your message and to meet any applicable reporting …
4 of Total
Information for Existing Suppliers & Accounts Payable | Incyte.com
… United Kingdom Luxembourg Required field. Message 200 character(s) left Required field. …
5 of Total
Corporate Governance | Incyte
… auditcommittee@incyte.com (a copy of this message will also be directed to Incyte’s General …
6 of Total
Progress in Focus: Our Global Responsibility | Incyte Stories
… therefore their emissions, electricity usage and square footage are excluded from these …
7 of Total
… whose beneficial ownership of securities are disaggregated from that of the Reporting Business …
8 of Total
Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults wi
Press Release View all news Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic
9 of Total
Culture & Careers | Incyte.com
… trying to find that molecule that has the best balance of all the properties that we need.” … healthy lives, achieve a proper work/life balance, manage finances and more. …
10 of Total
Compliance & Transparency | Incyte.com
… healthy lives, achieve a proper work/life balance, manage finances and more. Data Privacy: …